Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATIMOR: Modified SCRT + CAPOX + Tislelizumab for Rectal Cancer
NCT06333769Phase 2Completed
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in rectal cancer, sponsored by Fujian Medical University Cancer Hospital. Started Jul 2024; status: completed.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06333769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333769.